Magazine Article | July 3, 2023

I-MAK's Quest To Trim The Biopharmaceutical Patent Thicket

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

How long should a new drug be protected against lower- cost generic or biosimilar competitors? Established patent law provides an answer, and mechanisms exist in the U.S. to challenge patents believed to be invalid, unduly broad, obvious, or otherwise problematic. However, members of the American public — commonly known as patients, caregivers, and others without a direct business interest at stake — do not have meaningful channels for challenging patents that effectively determine drug access and affordability, a situation that the Initiative for Medicines, Access, and Knowledge (I-MAK) is fighting to change.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader